PMID- 29276366
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1068-0640 (Print)
IS  - 1068-0640 (Linking)
VI  - 24
IP  - 5
DP  - 2017 Sep
TI  - Interstitial Pneumonia with Autoimmune Features: Overview of proposed criteria 
      and recent cohort characterization.
PG  - 191-196
LID - 10.1097/CPM.0000000000000227 [doi]
AB  - The accurate diagnosis of interstitial lung disease (ILD) is essential for 
      optimal prognostication and management. While connective tissue disease (CTD) is 
      among the most common causes of ILD, some patients have features suggestive of 
      autoimmunity without meeting criteria for a specific CTD. To help define and 
      study this disease entity more uniformly, a 2015 research statement proposed 
      consensus-based criteria and coined the term "interstitial pneumonia with 
      autoimmune features" (IPAF). In this review, we summarize and compare previously 
      proposed criteria to characterize these patients, provide an overview of the IPAF 
      criteria and highlight recent investigations aimed at characterizing IPAF 
      cohorts. We then call attention to questions that have arisen with the 
      application of the IPAF criteria and discuss future areas of study.
FAU - Lee, Cathryn T
AU  - Lee CT
AD  - Department of Medicine, Section of Pulmonary and Critical Care, University of 
      Chicago, Chicago, IL.
FAU - Oldham, Justin M
AU  - Oldham JM
AD  - Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep 
      Medicine, University of California, Davis, Sacramento, CA.
LA  - eng
GR  - KL2 TR001859/TR/NCATS NIH HHS/United States
GR  - UL1 TR001860/TR/NCATS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Clin Pulm Med
JT  - Clinical pulmonary medicine
JID - 9421562
PMC - PMC5739083
MID - NIHMS895323
OTO - NOTNLM
OT  - connective tissue disease (CTD)
OT  - idiopathic pulmonary fibrosis (IPF)
OT  - interstitial lung disease (ILD)
OT  - interstitial pneumonia with autoimmune features (IPAF)
COIS- Conflicts of Interest: None declared for Dr. Lee. Dr. Oldham has received 
      speaking fees and sat on advisory boards for Genentech and Boehringer Ingelheim.
EDAT- 2017/12/26 06:00
MHDA- 2017/12/26 06:01
PMCR- 2018/09/01
CRDT- 2017/12/26 06:00
PHST- 2017/12/26 06:00 [entrez]
PHST- 2017/12/26 06:00 [pubmed]
PHST- 2017/12/26 06:01 [medline]
PHST- 2018/09/01 00:00 [pmc-release]
AID - 10.1097/CPM.0000000000000227 [doi]
PST - ppublish
SO  - Clin Pulm Med. 2017 Sep;24(5):191-196. doi: 10.1097/CPM.0000000000000227.